IR Pharma company logo
  • Company overview
  • Meet the team
  • Why we're different;
  • Technology - The drug development process at IRP; The Drug Evaluation Process; Model systems
  • Portfolio
  • Contact us

  • Acute and chronic models
    of airway inflammation


    IR Pharma will have a presence
    at the following conferences.
    Contact us to arrange
    a meeting with one of the team.

    May 19-24, 2017
    American Thoracic Society
    Annual Conference.
    Washington DC, USA.

    September 9-13, 2017
    European Respiratory Society
    Milan, Italy.

    Evaluation process,
    new treatments . . .


    The IR Pharma evaluation process systematically provides models delivering endpoint measurements for:

    • Acute and chronic models of allergic asthma;
    • inflammation;
    • experimental and therapeutic dose ranging;
    • lung function: invasive and non-invasive - EAR, LAR and AHR;
    • histopathology;
    • non-invasive biomarkers (exhaled indicators).

    Chronic Obstructive Pulmonary Disease (COPD)

    • Acute and chronic models of smoke induced airway inflammation in three different species;
    • steroid sensitive and resistant models of COPD (inflammation and emphysema).

    Models are available delivering endpoint measurements for:

    • Lung Function;
    • inflammation;
    • histopathology;
    • imaging;
    • Isolated Tissue Bio-Assay.


    In line with increased demand for means of evaluating both new treatments aimed at cough relief and to provide sensitive methods for detecting unwanted induction of cough by new drugs, IR Pharma has developed a range of tests and models based on both human- and animal-tissue samples, designed to investigate cough potentiation and treatment. They include:

    • a unique human vagus nerve model that allows proof of concept profiling in human tissue;
    • induced cough models (to a range of exogenous and endogenous tussive agents);
    • induced exacerbated cough (for example, post-smoke exposure).